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I am going to endeavour to cover 3 questions that arise with regard to orthotopic liver 
transplantation, that is to say regarding liver replacement: (1) What are the indications for 
hepatic transplantation? (2) What have been the results? (3) What are the Plospects for 
their future improvement? 
As a reminder of what exactly is implied by orthotopic liver transplantation, with this 
operation the diseased native liver is removed, thus creating a space which is to accom-
modate the cadaveric graft. Orthotopic liver transplantation is often very difficult, mostly 
because of the existing liver pathology that essentially always engenders a severe portal 
hypertension and produces extensive venous collaterals; thus the removal of the native 
liver may indeed well be an extremely formidable undertaking. Revascularization of the 
graft is performed in as anatomically normal a way as is possible - anastomosing the 
portal vein and hepatic artery end-to-end and reconstructing the vena cava above and 
below the liver. 
By far the most unsatisfactory aspect of this operation so far has been adequate biliary 
duct reconstruction; for most of our cases we have anastomosed the gallbladder to the 
duodenum after ligating the distal common bile duct. This hook-up has many real advan-
tages under conditions of immunosuppression because it can be performed without stents 
and drains; nevertheless, there have been a number of fatal complications connected with 
these cholecystoduodenostomies, an important point to which I will return later. 
With these preliminary remarks I shall now tum to the first question - what are the 
indications for this operation? In the beginning we thought that the ideal reason for liver 
replacement should be primary hepatic malignancies, including hepatomas, typically 
exemplified by the kind of extensive hepatoma we treated in this way in the early trials. 
Our enthusiasm was quickly dampened by a repetitive experience such as we encountered 
in the following typical individual case. 
The chest X-ray of a IS-year-old boy a few weeks after a successful orthotopic liver 
transplantation for a gigantic hepatoma already showed evidence of a small pUlmonary 
metastasis. He died 143 days after the operation with his lungs almost replaced by 
metastases. During this same interval his new liver was similarly invaded as could be 
followed with serial scans. There was evidence of metastases at all times from 3 months 
onwards after the operation. 
With the destruction of his liver the patient became secondarily jaundiced and he 
finally died of combined hepatic and pulmonary insufficiency. At autopsy his lungs were 
one mass of tumour. The same was true of the transplanted liver to such an extent that 
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only a tiny remnant of normal hepatic tissue remained. We have had a half dozen other 
so-called successful liver transplantations with subsequent widespread metastases and in 
actual fact 3 of our patients died over one year post transplantation from this complica-
tion. 
Nevertheless, it is a bit early to conclude once and for all that liver transplantation 
cannot be used to treat a hepatoma, which is also clearly illustrated by another case. In 
the liver of a child with biliary atresia a small 2 cm hepatoma was found purely as an 
incidental pathological feature. The child was referred from the Illinois Research Hospital 
of Chicago. She has a perfect result without any evidence of tumour recurrence 2.5 years 
lat"r. Long survival after liver replacement for a hepatoma has also been reported by 
CaIne of Cambridge, Deloze of Montreal and Fortner of New York. Nevertheless, I 
personally would prefer not to do more liver replacements for hepatomas at this time 
since the high incidence of metastases (80% in our hands) has beclouded the kind of 
conclusions that must be reached properly to evaluate any new procedure. 
It has seemed possible that the outlook might be rather less gloomy if the malignant 
tumour were of some kind other than a hepatoma. I would not be surprised if non-
resectable cholangiocarcinomas proved to be good candidates. Then there are the rare 
neoplasms: a gross specimen with widespread multifocal primaries was seen in a 
52-year-old man who had a haemangioendothelial sarcoma. The neoplasm kills with in-
credible swiftness, usually within a few weeks and by intra-abdominal haemorrhage or by 
the development of hepatic insufficiency rather than by tumoral spread. We treated this 
patient in 1971. Postoperatively, the bilirubin fell from 40 to nearly normal, along with 
an improvement in other liver functions. Then the patient survived a severe rejection 
which was eventually completely reversed. After achieving nearly normal liver function 
for more than 3 months, this patient also unfortunately developed widespread pulmonary 
metastases, as well as an extensive tumour recurrence in his liver graft. Thus we have here 
one more characteristic example of the usual futility of treating hepatic malignancy with 
a hepatic transplantation. 
I should like to draw your attention to the fact that one of the immunosuppressive 
agents used for this patient was cyclophosphamide rather than Imuran. Cyclophos-
phamide itself is one of the most widely used of the anti-cancer chemotherapeutic drugs. 
It is also one of the best immunosuppressants. In addition, ALG and prednisone were also 
used. 
Although I sincerely apologize for starting in such a seemingly negative way about the 
indications for liver replacement, this is one way of indicating that really the important 
future for hepatic transplantation is in the treatment of benign hepatic disease. I will not 
even bother to list the diseases for you since the end-stage is always the same. In fact, the 
general position we adopt now is that anyone under 40, who is not a sociopath and who 
is dying of hepatic insufficiency should theoretically be a suitable candidate for a liver 
transplantation. The most common diagnoses would of course be cirrhosis, chronic ag-
gressive hepatitis, and biliary atresia. 
The longest survivor in the world to date after a liver transplantation was a boy whose 
operation was in July 1968. There was a very minimal rejection crisis in the second 
postoperative month. His liver was biopsied 3 years later and was found to be almost 
normal, then suddenly just before Christmas 1971 he developed massive hepatic necrosis 
for which the aetiological explanation has not so far been clarified although late rejection 
may well have been the responsible factor. He died of acute hepatic insufficiency a few 
days later after a total survival time of 3.5 years, happily all of which was in good health, 
Another patient with benign disease was a child suffering from Wilson's disease which 
led to cirrhosis and finally to profound liver failure. After the operation he had a grave 
rejection crisis which eventually reversed and with an ultimately good result he is still 
alive to date after more than 2.5 years. He has returned to his home in Ohio where he 
now goes to school. 
As many of you know, Wilson's disease is an inborn error of metabolism of which the 
precise pathophysiology has never been completely worked out. The essential biochemi-
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cal finding is a deposition of copper in all tissues, including the liver and the brain. The 
characteristic Kayser-Kleischer rings by which the ophthalmologist can make the diagno-
sis are in fact nothing more than copper accumulations in the cornea. The information we 
have about this case leads us to believe that this copper accumulation does not occur post 
transplantation; on the contrary, the tissue copper probably remains normal. After the 
operation there was a massive cupruresis which lasted for almost 6 months and which was 
augmented in the end by a course of penicillamine. At this time the liver was biopsied and 
then biopsy was repeated after 1.5 years and after 2.5 years; on all 3 occasions the liver 
copper content was entirely normal. 
We also treated another patient with Wilson's disease, this time more than one year 
ago. In the case of this second patient the main indication for proceeding was his 
extremely severe neurological involvement that was not able to be controlled by penicil-
lamine therapy; in fact, the recipient was so neurologically crippled that he even had 
some respiratory distress. The first important point to note is that immunosuppressive 
treatment was again with cyclophosphamide (or Cytoxan) instead of with Imuran and in 
addition to the cyclophosphamide, horse ALG and prednisone were administered. The 
second important point is that rejection probably never occurred in this patient. There 
was a marked deterioration of hepatic function in the second postoperative month at 
which time the boy became jaundiced and had rises in his transaminases. This was 
probably not rejection as at the same time he developed Australia antigenaemia, with 
prodigious increase in his complement fixation titres. Immunosuppression was not inten-
sified and he spontaneously recovered. The reason for mentioning this second point is 
that we now realize how many factors other than rejection can cause a deterioration of 
the hepatic homograft function. The most important of these non-immunological com-
plications are serum hepatitis, such as evidenced here, biliary duct obstruction, which I 
shall come back to later since it is a much dreaded complication, and drug-induced 
hepatotoxicity. 
This concludes my remarks about the indications for hepatic transplantation. If 
perchance I have not made my position entirely clear, I can aptly summarize it with one 
sentence. We believe the situation is completely analogous to that applying to renal 
transplantation in which field benign disease is also the primary indication for treatment. 
I now pass to the second question, namely what are the results obtained? Between the 
spring of 1963 and July 1967, 7 attempts at an orthotopic liver transplantation were 
made in Denver, all of which failed with death in 21 days or even less. Our own 
experience, including these cases and all subsequent ones undertaken until one year ago, 
comprises 42 cases. A survival time of at least one year was obtained for all of these 42 
recipients (26%). This record cannot be described as disgraceful as all these patients were 
doomed to certain and early death, but it can certainly stand improvement. 
As I already mentioned, the most common causes for late failures were carcinomatosis 
and late rejection, accounting for 3 of the deaths each after one year, while serum 
hepatitis caused 2 late deaths. The whole question of serum hepatitis in transplant 
patients is just beginning to unfold but there is plenty of reason to know that potentially 
it is a most serious matter. Liver disease and specifically hepatitis in renal transplant 
patients is a very common complication, occurring in 10-20% of all kidney recipients in 
our centre. The incidence of serum hepatitis in our liver patients is even higher and I have 
already mentioned one example of this. In view of these observations, is there any hope 
of treating fatal serum hepatitis by a liver transplantation? I must confess that I do not 
know the answer to this question. However, I would like to tell you about one extra-
ordinary patient whose reason for liver transplantation was chronic aggressive hepatitis, 
Australia antigen positive. She was in profound hepatic failure. Transplantation was done 
in August 1970. The Australia antigen became negative for almost 2 months and then 
returned to positive at the same time as she had a clinical bout of acute serum hepatitis. 
She recovered from this but her Australia antigen remained positive. A repeat biopsy 14 
and 18 months after transplantation revealed that there was a recurrence of the chronic 
aggressive hepatitis in her transplanted liver and she died from a nocardial infection 20 
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months postoperatively. The aggressive hepatitis had progressed; nevertheless, herh,ealth 
had been reasonably satisfactory for most of her time of survival and for this patient 
meaningful life was prolonged. In view of this the issue as to whether more similar 
patients to this one should be so treated is perhaps more of a philosophical nature than it 
is a medical one. 
I will now turn to the third question I posed at the outset, namely what are the 
prospects of improving the outlook after liver replacement, at the same time making the 
assumption that only reasonable candidates with non-malignant disease are accepted. 
First of all, we are absolutely convinced that one of the real Achilles heels of this 
procedure is ineffective reconstruction of the biliary duct. 
Using cholecystoduodenostomy we have experienced obstruction at or near the junc-
tion of the common and cystic ducts. The true nature of the lesion can be appreciated by 
an operative cholangiogram performed with the Foley catheter inserted into the gall-
bladder; the obstructed duct system is quite obvious. This was corrected in 2 cases at 
reoperation but too late, all 4 of the patients with this lesion died. Dr. K.A. Porter of 
London has examined tissues from these homograft biliary ducts and gallbladders. He 
found widespread evidence of cytomegalovirus (CMV) and ulceration apparently caused 
by this agent; thus this kind of obstruction may at least stem from a partially infectious 
aetiology. 
In 4 recent cases of liver transplantation we have performed choledochoduodenostomy 
by the method of passing the common duct through a short duodenal tunnel and then 
everting it with a few sutures. Unfortunately the choledochoduodenostomy disrupted in 
one of these patients leading eventually to death from a biliary peritonitis; consequently 
we have now changed back to cholecystoduodenostomy as a routine. However, we now 
wish to follow a policy of early re-exploration, cholangiography, and the consideration of 
a secondary repair if postoperative jaundice develops and is persisten t. 
In addition to proving the correct management and judgment regarding possible 
homograft biliary obstruction, we believe it is important to try to use immunosuppressive 
agents that have low hepatotoxicity and with this objective we have switched since early 
last year to cyclophosphamide instead of Imuran for all our new cases. It must be 
emphasized that the usefulness of this major change will require much more evaluation 
before it can be generally recommended. 
Liver transplantation can be a very discouraging field. Because of our apparent 
inability to improve our results, we declared a moratorium for almost the entire latter 
half of 1971, but then we began again in January 1972. We have treated 5 patients, all 
with triple drug immunosuppression, including cyclophosphamide. One died of hepatic 
artery thrombosis, the other 4 are still alive, all with excellent liver function from 1 to 4 
months postoperatively. They represent the best group of liver transplant recipients that 
we have ever seen. We hope that they are providing some useful insight into the next great 
phase in the development of this difficult surgical field, but of course it is too soon to 
assert this as a definitive opinion. 
I will summarize now by giving a brief answer to each of the 3 questions I posed at the 
beginning. First, the prime indication for liver replacement is non-neoplastic hepatic 
disease. Secondly, the I-year survival rate in our clinic for all patients treated up to one 
year ago was between 25% and 30%. Thirdly, there is good reason for considerable 
optimism that this survival rate can be much improved by better technical performance 
and more especially by improved biliary duct drainage. Some recent developments in 
immunosuppression when cyclophosphamide has been used to replace or supplement 
Imuran may also be beneficial. 
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